Delaware
|
39-0394230
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
No.)
|
Large
accelerated filer x
|
Accelerated
filer ¨
|
Non-accelerated
filer ¨ (Do not check if
a smaller reporting company)
|
Smaller
reporting company ¨
|
Three Months Ended
|
Six Months Ended
|
||||||||||||
June 30
|
June
30
|
||||||||||||
(Millions
of dollars, except per share amounts)
|
2009
|
2008
|
2009
|
2008
|
|||||||||
Net
Sales
|
$
|
4,727
|
$
|
5,006
|
$
|
9,220
|
$
|
9,819
|
|||||
Cost of products
sold
|
3,154
|
3,522
|
6,193
|
6,879
|
|||||||||
Gross
Profit
|
1,573
|
1,484
|
3,027
|
2,940
|
|||||||||
Marketing, research and general
expenses
|
923
|
827
|
1,672
|
1,626
|
|||||||||
Other (income) and expense,
net
|
41
|
7
|
118
|
-
|
|||||||||
Operating
Profit
|
609
|
650
|
1,237
|
1,314
|
|||||||||
Interest income
|
6
|
8
|
14
|
16
|
|||||||||
Interest expense
|
(71
|
)
|
(74
|
)
|
(144
|
)
|
(148
|
)
|
|||||
Income
Before Income Taxes, Equity Interests and Extraordinary
Loss
|
544
|
584
|
1,107
|
1,182
|
|||||||||
Provision for income
taxes
|
(158
|
)
|
(174
|
)
|
(322
|
)
|
(339
|
)
|
|||||
Income
Before Equity Interests and Extraordinary Loss
|
386
|
410
|
785
|
843
|
|||||||||
Share of net income of equity
companies
|
44
|
49
|
76
|
92
|
|||||||||
Extraordinary loss, net of income
taxes
|
-
|
(8
|
)
|
-
|
(8
|
)
|
|||||||
Net
Income
|
430
|
451
|
861
|
927
|
|||||||||
Net income attributable to
noncontrolling interests
|
(27
|
)
|
(34
|
)
|
(51
|
)
|
(69
|
)
|
|||||
Net
Income Attributable to Kimberly-Clark Corporation
|
$
|
403
|
$
|
417
|
$
|
810
|
$
|
858
|
|||||
Per
Share Basis:
|
|||||||||||||
Basic
|
|||||||||||||
Before extraordinary
loss
|
$
|
.97
|
$
|
1.01
|
$
|
1.95
|
$
|
2.06
|
|||||
Extraordinary
loss
|
-
|
(.02
|
)
|
-
|
(.02
|
)
|
|||||||
Net Income Attributable to
Kimberly-Clark Corporation
|
$
|
.97
|
$
|
.99
|
$
|
1.95
|
$
|
2.04
|
|||||
Diluted
|
|||||||||||||
Before extraordinary
loss
|
$
|
.97
|
$
|
1.01
|
$
|
1.95
|
$
|
2.05
|
|||||
Extraordinary
loss
|
-
|
(.02
|
)
|
-
|
(.02
|
)
|
|||||||
Net Income Attributable to
Kimberly-Clark Corporation
|
$
|
.97
|
$
|
.99
|
$
|
1.95
|
$
|
2.03
|
|||||
Cash Dividends
Declared
|
$
|
.60
|
$
|
.58
|
$
|
1.20
|
$
|
1.16
|
June 30,
|
December 31,
|
|||||
(Millions
of dollars)
|
2009
|
2008
|
||||
ASSETS
|
||||||
Current
Assets
|
||||||
Cash and cash
equivalents
|
$
|
591
|
$
|
364
|
||
Accounts receivable,
net
|
2,331
|
2,492
|
||||
Inventories
|
2,058
|
2,493
|
||||
Other current
assets
|
484
|
464
|
||||
Total Current
Assets
|
5,464
|
5,813
|
||||
Property
|
16,331
|
15,723
|
||||
Less accumulated
depreciation
|
8,523
|
8,056
|
||||
Net Property
|
7,808
|
7,667
|
||||
Investments
in Equity Companies
|
369
|
324
|
||||
Goodwill
|
2,981
|
2,743
|
||||
Long-Term
Notes Receivable
|
605
|
603
|
||||
Other
Assets
|
919
|
939
|
||||
$
|
18,146
|
$
|
18,089
|
|||
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
||||||
Current
Liabilities
|
||||||
Debt payable within one
year
|
$
|
373
|
$
|
1,083
|
||
Accounts payable
|
1,512
|
1,603
|
||||
Accrued expenses
|
2,000
|
1,723
|
||||
Other current
liabilities
|
421
|
343
|
||||
Total Current
Liabilities
|
4,306
|
4,752
|
||||
Long-Term
Debt
|
5,490
|
4,882
|
||||
Noncurrent
Employee Benefits
|
1,962
|
2,593
|
||||
Long-Term
Income Taxes Payable
|
151
|
189
|
||||
Deferred
Income Taxes
|
209
|
193
|
||||
Other
Liabilities
|
205
|
187
|
||||
Redeemable
Preferred and Common Securities of
Subsidiaries
|
1,046
|
1,032
|
||||
Stockholders’
Equity
|
||||||
Kimberly-Clark
Corporation
|
4,496
|
3,878
|
||||
Noncontrolling
Interests
|
281
|
383
|
||||
Total Stockholders’
Equity
|
4,777
|
4,261
|
||||
$
|
18,146
|
$
|
18,089
|
Six Months
|
|||||||
Ended June 30
|
|||||||
(Millions
of dollars)
|
2009
|
2008
|
|||||
Operating
Activities
|
|||||||
Net income
|
$
|
861
|
$
|
927
|
|||
Extraordinary loss, net of income
taxes
|
-
|
8
|
|||||
Depreciation and
amortization
|
367
|
400
|
|||||
Stock-based
compensation
|
28
|
25
|
|||||
Decrease (increase) in operating
working capital
|
886
|
(193
|
)
|
||||
Deferred income
taxes
|
(63
|
)
|
50
|
||||
Net losses on asset
dispositions
|
21
|
17
|
|||||
Equity companies’ earnings in
excess of dividends paid
|
(51
|
)
|
(53
|
)
|
|||
Postretirement
benefits
|
(354
|
)
|
(4
|
)
|
|||
Other
|
(6
|
)
|
20
|
||||
Cash Provided by
Operations
|
1,689
|
1,197
|
|||||
Investing
Activities
|
|||||||
Capital spending
|
(396
|
)
|
(434
|
)
|
|||
Acquisition of businesses, net of
cash acquired
|
(165
|
)
|
(76
|
)
|
|||
Proceeds from sales of
investments
|
19
|
39
|
|||||
Proceeds from dispositions of
property
|
2
|
1
|
|||||
Net (increase) decrease in time
deposits
|
(40
|
)
|
44
|
||||
Investments in marketable
securities
|
-
|
(9
|
)
|
||||
Other
|
(16
|
)
|
(1
|
)
|
|||
Cash Used for
Investing
|
(596
|
)
|
(436
|
)
|
|||
Financing
Activities
|
|||||||
Cash dividends
paid
|
(488
|
)
|
(468
|
)
|
|||
Net (decrease) increase in
short-term debt
|
(86
|
)
|
213
|
||||
Proceeds from issuance of
long-term debt
|
2
|
34
|
|||||
Repayments of long-term
debt
|
(32
|
)
|
(35
|
)
|
|||
Cash paid on redeemable preferred
securities of subsidiary
|
(26
|
)
|
(20
|
)
|
|||
Shares purchased from
noncontrolling interests
|
(278
|
)
|
-
|
||||
Proceeds from exercise of stock
options
|
23
|
67
|
|||||
Acquisitions of common stock for
the treasury
|
(6
|
)
|
(437
|
)
|
|||
Other
|
2
|
(33
|
)
|
||||
Cash Used for
Financing
|
(889
|
)
|
(679
|
)
|
|||
Effect
of Exchange Rate Changes on Cash and Cash Equivalents
|
23
|
(9
|
)
|
||||
Increase
in Cash and Cash Equivalents
|
227
|
73
|
|||||
Cash
and Cash Equivalents, beginning of year
|
364
|
473
|
|||||
Cash
and Cash Equivalents, end of period
|
$
|
591
|
$
|
546
|
Three
Months
Ended
June 30
|
Six
Months
Ended
June 30
|
|||||||||||||||
(Millions
of dollars)
|
2009
|
2008
|
2009
|
2008
|
||||||||||||
Net
Income
|
$
|
430
|
$
|
451
|
$
|
861
|
$
|
927
|
||||||||
Other
Comprehensive Income, Net of Tax:
|
||||||||||||||||
Unrealized currency translation
adjustments
|
646
|
39
|
285
|
330
|
||||||||||||
Employee postretirement
benefits
|
145
|
6
|
177
|
-
|
||||||||||||
Other
|
(9
|
)
|
10
|
(15
|
)
|
(12
|
)
|
|||||||||
Total
Other Comprehensive Income, Net of Tax
|
782
|
55
|
447
|
318
|
||||||||||||
Comprehensive
Income
|
1,212
|
506
|
1,308
|
1,245
|
||||||||||||
Comprehensive income
attributable to noncontrolling interests
|
62
|
19
|
53
|
40
|
||||||||||||
Comprehensive
Income Attributable to Kimberly-Clark Corporation
|
$
|
1,150
|
$
|
487
|
$
|
1,255
|
$
|
1,205
|
As
Previously Reported
|
As
Recast
|
|||||||||||||||
Basic
|
Diluted
|
Basic
|
Diluted
|
|||||||||||||
2008:
|
||||||||||||||||
First
Quarter
|
$
|
1.05
|
$
|
1.04
|
$
|
1.05
|
$
|
1.04
|
||||||||
Second
Quarter
|
1.00
|
0.99
|
0.99
|
0.99
|
||||||||||||
Six
Months
|
2.05
|
2.04
|
2.04
|
2.03
|
||||||||||||
Third
Quarter
|
1.00
|
0.99
|
0.99
|
0.99
|
||||||||||||
Fourth
Quarter
|
1.01
|
1.01
|
1.01
|
1.01
|
||||||||||||
Full
Year
|
4.06
|
4.04
|
4.04
|
4.03
|
||||||||||||
2007
|
4.13
|
4.09
|
4.11
|
4.08
|
||||||||||||
2006
|
3.27
|
3.25
|
3.26
|
3.24
|
|
•
|
how
investment allocation decisions are made,
|
|
|
•
|
major
categories of plan assets,
|
|
|
•
|
inputs
and valuation techniques used to measure fair value,
|
|
|
•
|
the
effect of fair value measurements using significant unobservable inputs on
year-to-year changes in plan assets, and
|
|
|
•
|
significant
concentrations of risk within plan
assets.
|
Fair
Value
Measurements
|
|||||||
(Millions
of dollars)
|
June
30,
2009
|
Level
1
|
Level
2
|
||||
Assets
|
|||||||
Company-owned
life insurance (“COLI”)
|
$ 40
|
$ -
|
$ 40
|
||||
Available-for-sale
securities
|
11
|
11
|
-
|
||||
Derivatives
|
75
|
-
|
75
|
||||
Total
|
$126
|
$11
|
$115
|
||||
Liabilities
|
|||||||
Derivatives
|
$150
|
$ -
|
$150
|
Carrying
|
Estimated
|
|||||||
(Millions
of dollars)
|
Amount
|
Fair
Value
|
||||||
Assets
|
||||||||
Cash and cash equivalents(a)
|
$
|
591
|
$
|
591
|
||||
Time deposits(b)
|
166
|
166
|
||||||
Long-term notes receivable(c)
|
605
|
575
|
||||||
Liabilities
and Redeemable Preferred and Common Securities of
Subsidiaries
|
||||||||
Short-term debt(d)
|
330
|
330
|
||||||
Long-term monetization
loans(c)
|
616
|
611
|
||||||
Other long-term
debt(e)
|
4,917
|
5,290
|
||||||
Redeemable preferred and common
securities of subsidiaries(f)
|
1,046
|
1,115
|
|
(a)
|
Cash
equivalents are comprised of certificates of deposit, time deposits and
other interest-bearing investments with original maturity dates of 90 days
or less, all of which are recorded at cost, which approximates fair
value.
|
|
(b)
|
Time
deposits are comprised of deposits with original maturities of more than
90 days but less than one year, all of which are recorded at cost, which
approximates fair value.
|
|
(c)
|
Long-term
notes receivable represent held-to-maturity securities, which arose from
the sale of nonstrategic timberlands and related assets. The
notes, which are backed by irrevocable standby letters of credit issued by
money center banks, are held by two consolidated financing entities. The
financing entities have outstanding long-term monetization loans secured
by the notes. The maturity dates of the two loans were extended
in June 2009. This extension had no effect on the primary
beneficiary determination. The Corporation remains the primary
beneficiary and continues to consolidate the financing
entities.
|
Description
|
Face
Value
|
Carrying
Amount
|
Maturity
|
Interest
Rate(1)(2)
|
||||
Note
1
|
$397
|
$391
|
09/30/2014
|
LIBOR
minus 15 bps
|
||||
Note
2
|
220
|
214
|
07/07/2011
|
LIBOR
minus 12.5 bps
|
||||
Loan
1
|
397
|
396
|
09/30/2010
|
LIBOR
plus 127 bps
|
||||
Loan
2
|
220
|
220
|
07/01/2010
|
LIBOR
plus 110 bps
|
|
(d)
|
Short-term
debt is comprised of U.S. commercial paper with original maturities up to
90 days and other similar short-term debt issued by non-U.S. subsidiaries,
all of which are recorded at cost, which approximates fair
value.
|
|
(e)
|
Other
long-term debt includes the
current portion ($43 million) of these debt
instruments.
|
|
(f)
|
The
Redeemable Preferred Securities are not traded in active
markets. Accordingly, their fair values were calculated using a
pricing model that compares the stated spread to the fair value spread to
determine the price at which each of the financial instruments should
trade. The model uses the following inputs to calculate fair
values: current benchmark rate, fair value spread, stated spread, maturity
date and interest payment dates. The fair values of the
Redeemable Common Securities were based on an independent third-party
appraisal.
|
(Millions
of dollars)
|
Three
Months
Ended
June 30
2009
|
|||
Personal
Care
|
$
|
41
|
||
Consumer
Tissue
|
42
|
|||
K-C
Professional & Other
|
14
|
|||
Health
Care
|
6
|
|||
Corporate
& Other
|
7
|
|||
Total
|
$
|
110
|
Three Months
|
|||
Ended
June 30
|
|||
(Millions
of dollars)
|
2009
|
||
Cost of products sold
|
$
|
27
|
|
Marketing, research and general expenses
|
83
|
||
Provision for income taxes
|
(32
|
)
|
|
Net Charges
|
$
|
78
|
June
30, 2009
|
December
31, 2008
|
||||||||||||||||||||||||
Summary
of Inventories (Millions of dollars)
|
LIFO
|
Non-
LIFO
|
Total
|
LIFO
|
Non-
LIFO
|
Total
|
|||||||||||||||||||
At
the lower of cost determined on the
|
|||||||||||||||||||||||||
FIFO or weighted-average cost
methods
|
|||||||||||||||||||||||||
or market:
|
|||||||||||||||||||||||||
Raw materials
|
$
|
122
|
$
|
261
|
$
|
383
|
$
|
150
|
$
|
367
|
$
|
517
|
|||||||||||||
Work in process
|
183
|
119
|
302
|
246
|
133
|
379
|
|||||||||||||||||||
Finished goods
|
549
|
737
|
1,286
|
758
|
832
|
1,590
|
|||||||||||||||||||
Supplies and
other
|
-
|
278
|
278
|
-
|
262
|
262
|
|||||||||||||||||||
854
|
1,395
|
2,249
|
1,154
|
1,594
|
2,748
|
||||||||||||||||||||
Excess
of FIFO or weighted-average
|
|||||||||||||||||||||||||
cost over LIFO
cost
|
(191
|
)
|
-
|
(191
|
)
|
(255
|
)
|
-
|
(255
|
)
|
|||||||||||||||
Total
|
$
|
663
|
$
|
1,395
|
$
|
2,058
|
$
|
899
|
$
|
1,594
|
$
|
2,493
|
Defined
|
Other Postretirement
|
|||||||||||
Benefit Plans
|
Benefit Plans
|
|||||||||||
Three Months Ended June 30
|
||||||||||||
(Millions
of dollars)
|
2009
|
2008
|
2009
|
2008
|
||||||||
Service
cost
|
$
|
17
|
$
|
19
|
$
|
3
|
$
|
4
|
||||
Interest
cost
|
77
|
83
|
11
|
12
|
||||||||
Expected
return on plan assets
|
(67
|
)
|
(95
|
)
|
-
|
-
|
||||||
Recognized
net actuarial loss (gain)
|
25
|
15
|
-
|
(1
|
)
|
|||||||
Curtailment
|
21
|
-
|
-
|
-
|
||||||||
Other
|
-
|
3
|
1
|
1
|
||||||||
Net
periodic benefit cost
|
$
|
73
|
$
|
25
|
$
|
15
|
$
|
16
|
Defined
|
Other Postretirement
|
|||||||||||
Benefit Plans
|
Benefit Plans
|
|||||||||||
Six Months Ended June 30
|
||||||||||||
(Millions
of dollars)
|
2009
|
2008
|
2009
|
2008
|
||||||||
Service
cost
|
$
|
33
|
$
|
39
|
$
|
6
|
$
|
7
|
||||
Interest
cost
|
154
|
165
|
24
|
25
|
||||||||
Expected
return on plan assets
|
(132
|
)
|
(189
|
)
|
-
|
-
|
||||||
Recognized
net actuarial loss
|
68
|
29
|
-
|
-
|
||||||||
Curtailment
|
21
|
-
|
-
|
-
|
||||||||
Other
|
1
|
7
|
2
|
2
|
||||||||
Net
periodic benefit cost
|
$
|
145
|
$
|
51
|
$
|
32
|
$
|
34
|
Average Common Shares Outstanding
|
|||||||||
Three Months
|
Six Months
|
||||||||
Ended June 30
|
Ended June 30
|
||||||||
(Millions
of shares)
|
2009
|
2008
|
2009
|
2008
|
|||||
Average
shares outstanding
|
414.1
|
417.7
|
413.9
|
418.9
|
|||||
Participating
securities
|
1.5
|
1.8
|
1.7
|
1.7
|
|||||
Basic
|
415.6
|
419.5
|
415.6
|
420.6
|
|||||
Dilutive
effect of stock options
|
.1
|
1.3
|
.1
|
1.4
|
|||||
Dilutive
effect of restricted share and restricted share unit
awards
|
.2
|
.2
|
.2
|
.2
|
|||||
Diluted
|
415.9
|
421.0
|
415.9
|
422.2
|
|
·
|
Noncontrolling
interests are reported as an element of consolidated equity, thereby
eliminating the prior practice of classifying minority owners’ interests
within a mezzanine section of the balance
sheet.
|
|
·
|
Reported
net income includes the total income of all consolidated subsidiaries,
with separate disclosure on the face of the income statement of the split
of net income between the controlling and noncontrolling
interests.
|
|
·
|
Increases
and decreases in the noncontrolling ownership interest amount are
accounted for as equity transactions. If the controlling
interest loses control and deconsolidates a subsidiary, full gain or loss
on the transition is recognized.
|
|
·
|
Noncontrolling
interests, which are not redeemable at the option of the noncontrolling
interests, were reclassified from the mezzanine to equity, separate from
the parent’s stockholders’ equity, in the consolidated balance
sheet. Common securities, redeemable at the option of the
noncontrolling interest, carried at redemption value of approximately
$35 million are classified in a line item combined with redeemable
preferred securities of subsidiary in the consolidated balance
sheet.
|
|
·
|
Consolidated
net income was recast to include net income attributable to both
controlling and noncontrolling
interests.
|
Stockholders’
Equity
Attributable
to
|
||||||||||||||||
(Millions
of dollars)
|
Comprehensive
Income
|
The
Corporation
|
Noncontrolling
Interests
|
Redeemable
Securities
of
Subsidiaries
|
||||||||||||
Balance
at December 31, 2008
|
$
|
3,878
|
$
|
383
|
$
|
1,032
|
||||||||||
Purchase
of subsidiary shares
|
||||||||||||||||
from noncontrolling
interests
|
(170
|
)
|
(108
|
)
|
-
|
|||||||||||
Comprehensive
Income:
|
||||||||||||||||
Net income
|
$
|
861
|
810
|
23
|
28
|
|||||||||||
Other comprehensive
income,
net of tax:
|
||||||||||||||||
Unrealized
translation
|
285
|
299
|
(14
|
)
|
-
|
|||||||||||
Employee
postretirement
benefits
|
177
|
161
|
16
|
-
|
||||||||||||
Other
|
(15
|
)
|
(15
|
)
|
-
|
-
|
||||||||||
Total
Comprehensive Income
|
$
|
1,308
|
||||||||||||||
Stock-based
awards and other
|
30
|
-
|
12
|
|||||||||||||
Dividends
declared
|
(497
|
)
|
(18
|
)
|
-
|
|||||||||||
Return
on redeemable preferred
securities and
noncontrollinginterests
|
-
|
(1
|
)
|
(26
|
)
|
|||||||||||
Balance
at June 30, 2009
|
$
|
4,496
|
$
|
281
|
$
|
1,046
|
Stockholders’
Equity
Attributable
to
|
||||||||||||||||
(Millions
of dollars)
|
Comprehensive
Income
|
The
Corporation
|
Noncontrolling
Interests
|
Redeemable
Securities
of
Subsidiaries
|
||||||||||||
Balance
at December 31, 2007
|
$
|
5,224
|
$
|
463
|
$
|
1,026
|
||||||||||
Purchase
of subsidiary shares from noncontrolling interest
|
-
|
(30
|
)
|
(2
|
)
|
|||||||||||
Comprehensive
Income:
|
||||||||||||||||
Net income
|
$
|
927
|
858
|
41
|
28
|
|||||||||||
Other comprehensive
income,
net of tax:
|
||||||||||||||||
Unrealized
translation
|
330
|
354
|
(23
|
)
|
(1
|
)
|
||||||||||
Employee
postretirement
benefits
|
-
|
5
|
(5
|
)
|
-
|
|||||||||||
Other
|
(12
|
)
|
(12
|
)
|
-
|
-
|
||||||||||
Total
Comprehensive Income
|
$
|
1,245
|
||||||||||||||
Stock-based
awards and other
|
90
|
-
|
1
|
|||||||||||||
Shares
repurchased
|
(430
|
)
|
-
|
-
|
||||||||||||
Dividends
declared
|
(486
|
)
|
(39
|
)
|
-
|
|||||||||||
Return
on redeemable preferred
securities and noncontrolling
interests
|
-
|
(1
|
)
|
(20
|
)
|
|||||||||||
Balance
at June 30, 2008
|
$
|
5,603
|
$
|
406
|
$
|
1,032
|
Six
Months
Ended
June 30
|
||||||||
(Millions
of dollars)
|
2009
|
2008
|
||||||
Net
Income attributable to Kimberly-Clark Corporation
|
$
|
810
|
$
|
858
|
||||
Decrease
in Kimberly-Clark Corporation’s additional paid-in capital for purchase
of
|
||||||||
remaining
shares in its Andean subsidiary(a)
|
(133
|
)
|
-
|
|||||
Change
from net income attributable to Kimberly-Clark Corporation and
transfers
|
||||||||
to
noncontrolling interests
|
$
|
677
|
$
|
858
|
(a)
|
During
the first quarter of 2009, the Corporation acquired the remaining
approximate 31 percent interest in its Andean region subsidiary,
Colombiana Kimberly Colpapel S.A., for $289 million. In
accordance with SFAS 160, the acquisition was recorded as an equity
transaction that reduced noncontrolling interests, accumulated other
comprehensive income and additional paid-in capital classified in
stockholders’ equity by approximately $278 million and increased
investments in equity companies by approximately $11
million.
|
The
Effect of Derivative Instruments on the Consolidated Income
Statement
for
the Three Months Ended June 30, 2009 and 2008 – (Millions of
dollars)
|
||||||||||
Foreign
exchange contracts
|
Income
Statement Classification
|
Gain
or (Loss)
Recognized
in Income
|
||||||||
2009
|
2008
|
|||||||||
Fair
Value Hedges
|
Other
income and (expense), net
|
$
|
1
|
$
|
(4
|
)
|
||||
Undesignated
Hedging Instruments
|
Other
income and (expense), net(a)
|
$
|
(3
|
)
|
$
|
(23
|
)
|
Amount
of Gain or
(Loss)
Recognized
In
OCI
|
Income
Statement Classification of Gain or (Loss) Reclassified from
OCI
|
Gain
or (Loss) Reclassified from OCI into Income
|
||||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||||
Cash Flow Hedges
|
||||||||||||||||||
Interest
rate contracts
|
$
|
19
|
$
|
12
|
Interest
Expense
|
$
|
1
|
$
|
-
|
|||||||||
Foreign
exchange
contracts
|
(35
|
)
|
(7
|
)
|
Cost
of products sold
|
2
|
(12
|
)
|
||||||||||
Commodity
contract
|
2
|
5
|
Cost
of products sold
|
(11
|
)
|
2
|
||||||||||||
Total
|
$
|
(14
|
)
|
$
|
10
|
$
|
(8
|
)
|
$
|
(10
|
)
|
|||||||
Net Investment Hedges
|
||||||||||||||||||
Foreign
exchange
contracts
|
$
|
(5
|
)
|
$
|
(3
|
)
|
$
|
-
|
$
|
-
|
The
Effect of Derivative Instruments on the Consolidated Income
Statement
for
the Six Months Ended June 30, 2009 and 2008 – (Millions of
dollars)
|
||||||||||
Foreign
exchange contracts
|
Income
Statement Classification
|
Gain
or (Loss)
Recognized
in Income
|
||||||||
2009
|
2008
|
|||||||||
Fair
Value Hedges
|
Other
income and (expense), net
|
$
|
(14
|
)
|
$
|
(3
|
)
|
|||
Undesignated
Hedging Instruments
|
Other
income and (expense), net(a)
|
$
|
(79
|
)
|
$
|
5
|
Amount
of Gain or
(Loss)
Recognized
In
OCI
|
Income
Statement Classification of Gain or (Loss) Reclassified from
OCI
|
Gain
or (Loss) Reclassified from OCI into Income
|
||||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||||
Cash Flow Hedges
|
||||||||||||||||||
Interest
rate contracts
|
$
|
26
|
$
|
3
|
Interest
Expense
|
$
|
1
|
$
|
1
|
|||||||||
Foreign
exchange
contracts
|
(17
|
)
|
(29
|
)
|
Cost
of products sold
|
21
|
(23
|
)
|
||||||||||
Commodity
contract
|
(20
|
)
|
8
|
Cost
of products sold
|
(23
|
)
|
-
|
|||||||||||
Total
|
$
|
(11
|
)
|
$
|
(18
|
)
|
$
|
(1
|
)
|
$
|
(22
|
)
|
||||||
Net Investment Hedges
|
||||||||||||||||||
Foreign
exchange
contracts
|
$
|
(13
|
)
|
$
|
(5
|
)
|
$
|
-
|
$
|
-
|
(a)
|
The
majority of the gains and (losses) on these instruments arise from
derivatives entered into with third parties by the In-House
Bank. As previously noted, the In-House Bank also records gains
and (losses) on the translation of its non-U.S. dollar denominated
monetary assets and liabilities in earnings. Consequently, the
effect on earnings from the use of these non-designated derivatives is
substantially neutralized by the recorded transactional gains and
losses.
|
Fair
Values of Derivative Instruments
|
||||||||||
Asset
Derivatives
|
||||||||||
(Millions
of dollars)
|
June
30,
2009
|
June
30,
2008
|
||||||||
Balance
|
Balance
|
|||||||||
Sheet
|
Fair
|
Sheet
|
Fair
|
|||||||
Location
|
Value
|
Location
|
Value
|
|||||||
Derivatives
designated as hedging
instruments:
|
||||||||||
Interest rate
contracts
|
Other
assets
|
$
|
30
|
Other
assets
|
$
|
18
|
||||
Foreign exchange
contracts
|
Other
current assets
|
4
|
Other
current assets
|
4
|
||||||
Commodity
contracts
|
Other
assets
|
1
|
Other
current assets
|
5
|
||||||
Total
|
$
|
35
|
$
|
27
|
||||||
Undesignated
Derivatives:
|
||||||||||
Foreign exchange
contracts
|
Other
current assets
|
$
|
40
|
Other
current assets
|
$
|
13
|
||||
Total
asset derivatives
|
$
|
75
|
$
|
40
|
Fair
Values of Derivative Instruments
|
||||||||||
Liability
Derivatives
|
||||||||||
(Millions
of dollars)
|
June
30,
2009
|
June
30,
2008
|
||||||||
Balance
|
Balance
|
|||||||||
Sheet
|
Fair
|
Sheet
|
Fair
|
|||||||
Location
|
Value
|
Location
|
Value
|
|||||||
Derivatives
designated as hedging
instruments:
|
||||||||||
Foreign exchange
contracts
|
Accrued
expenses
|
$
|
42
|
Accrued
expenses
|
26
|
|||||
Commodity
contracts
|
Accrued
expenses
|
15
|
Accrued
expenses
|
-
|
||||||
Commodity
contracts
|
Other
liabilities
|
1
|
-
|
|||||||
Total
|
$
|
58
|
$
|
26
|
||||||
Undesignated
Derivatives:
|
||||||||||
Foreign exchange
contracts
|
Accrued
expenses
|
$
|
92
|
Accrued
expenses
|
$
|
6
|
||||
Total
liability derivatives
|
$
|
150
|
$
|
32
|
·
|
The
Personal Care segment manufactures and markets disposable diapers,
training and youth pants and swimpants; baby wipes; feminine and
incontinence care products; and related products. Products in
this segment are primarily for household use and are sold under a variety
of brand names, including Huggies, Pull-Ups, Little Swimmers, GoodNites,
Kotex, Lightdays, Depend, Poise and other brand
names.
|
·
|
The
Consumer Tissue segment manufactures and markets facial and bathroom
tissue, paper towels, napkins and related products for household
use. Products in this segment are sold under the Kleenex,
Scott, Cottonelle, Viva, Andrex, Scottex, Hakle, Page and other brand
names.
|
|
Note
9. (Continued)
|
·
|
The
K-C Professional & Other segment manufactures and markets facial and
bathroom tissue, paper towels, napkins, wipers and a range of safety
products for the away-from-home marketplace. Products in this
segment are sold under the Kimberly-Clark, Kleenex, Scott, WypAll,
Kimtech, KleenGuard, Kimcare and Jackson brand
names.
|
·
|
The
Health Care segment manufactures and markets disposable health care
products such as surgical gowns, drapes, infection control products,
sterilization wrap, face masks, exam gloves, respiratory products and
other disposable medical products. Products in this segment are
sold under the Kimberly-Clark, Ballard and other brand
names.
|
Three Months
|
Six Months
|
||||||||||||
Ended June 30
|
Ended June 30
|
||||||||||||
(Millions
of dollars)
|
2009
|
2008
|
2009
|
2008
|
|||||||||
NET
SALES:
|
|||||||||||||
Personal
Care
|
$
|
2,122
|
$
|
2,165
|
$
|
4,099
|
$
|
4,211
|
|||||
Consumer
Tissue
|
1,555
|
1,690
|
3,129
|
3,397
|
|||||||||
K-C
Professional & Other
|
736
|
840
|
1,387
|
1,601
|
|||||||||
Health
Care
|
335
|
306
|
633
|
604
|
|||||||||
Corporate
& Other
|
14
|
23
|
27
|
45
|
|||||||||
Intersegment
sales
|
(35
|
)
|
(18
|
)
|
(55
|
)
|
(39
|
)
|
|||||
Consolidated
|
$
|
4,727
|
$
|
5,006
|
$
|
9,220
|
$
|
9,819
|
Three Months
|
Six Months
|
||||||||||||
Ended June 30
|
Ended June 30
|
||||||||||||
(Millions
of dollars)
|
2009
|
2008
|
2009
|
2008
|
|||||||||
OPERATING PROFIT (reconciled to income before
|
|||||||||||||
income taxes):
|
|||||||||||||
Personal
Care
|
$
|
394
|
$
|
437
|
$
|
836
|
$
|
865
|
|||||
Consumer
Tissue
|
161
|
130
|
355
|
286
|
|||||||||
K-C
Professional & Other
|
102
|
111
|
182
|
208
|
|||||||||
Health
Care
|
62
|
30
|
110
|
76
|
|||||||||
Other
income and (expense), net(a)(b)
|
(41
|
)
|
(7
|
)
|
(118
|
)
|
-
|
||||||
Corporate
& Other(b)
|
(69
|
)
|
(51
|
)
|
(128
|
)
|
(121
|
)
|
|||||
Total
Operating Profit
|
609
|
650
|
1,237
|
1,314
|
|||||||||
Interest income
|
6
|
8
|
14
|
16
|
|||||||||
Interest expense
|
(71
|
)
|
(74
|
)
|
(144
|
)
|
(148
|
)
|
|||||
Income
Before Income Taxes
|
$
|
544
|
$
|
584
|
$
|
1,107
|
$
|
1,182
|
(a)
|
Other
income and (expense), net includes the following amounts of currency
transaction gains (losses).
|
Three Months
|
Six Months
|
|||||||||||||||
Ended June 30
|
Ended June 30
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Other
income and (expense), net
|
$
|
(20
|
)
|
$
|
(6
|
)
|
$
|
(96
|
)
|
$
|
6
|
(b)
|
Corporate
& Other and Other income and (expense), net include the following
amounts of pre-tax charges for the strategic cost
reductions.
|
Three
Months
|
Six
Months
|
||||||||
Ended
June 30
|
Ended
June 30
|
||||||||
2008
|
2008
|
||||||||
Corporate
& Other
|
$
|
(14
|
)
|
$
|
(37
|
)
|
|||
Other
income and (expense), net
|
(1
|
)
|
(2
|
)
|
·
|
Overview
of Second Quarter 2009 Results
|
·
|
Results
of Operations and Related
Information
|
·
|
Liquidity
and Capital Resources
|
·
|
New
Accounting Standards
|
·
|
Environmental
Matters
|
·
|
Business
Outlook
|
·
|
Net
sales decreased 5.6 percent.
|
·
|
Operating
profit and net income attributable to Kimberly-Clark Corporation decreased
6.3 percent and 3.4 percent,
respectively.
|
·
|
Cash
provided by operations was $997 million, an increase of 32.4 percent over
last year.
|
Net
Sales
|
2009
|
2008
|
||||
Personal
Care
|
$
|
2,122
|
$
|
2,165
|
||
Consumer
Tissue
|
1,555
|
1,690
|
||||
K-C
Professional & Other
|
736
|
840
|
||||
Health
Care
|
335
|
306
|
||||
Corporate
& Other
|
14
|
23
|
||||
Intersegment
sales
|
(35
|
)
|
(18
|
)
|
||
Consolidated
|
$
|
4,727
|
$
|
5,006
|
Percent Change in Net Sales Versus Prior Year
|
|||||||||||||||
Changes Due To
|
|||||||||||||||
Total
|
Volume
|
Net
|
Mix/
|
||||||||||||
Change
|
Growth
|
Price
|
Currency
|
Other
|
|||||||||||
Consolidated
|
(5.6
|
)
|
(2
|
)
|
5
|
(8
|
)
|
(1
|
)
|
||||||
Personal
Care
|
(2.0
|
)
|
-
|
6
|
(9
|
)
|
1
|
||||||||
Consumer
Tissue
|
(8.0
|
)
|
(3
|
)
|
4
|
(9
|
)
|
-
|
|||||||
K-C
Professional & Other
|
(12.4
|
)
|
(10
|
)
|
3
|
(7
|
)
|
2
|
|||||||
Health
Care
|
9.5
|
14
|
(1
|
)
|
(4
|
)
|
-
|
·
|
Personal
care net sales in North America decreased 4 percent versus the second
quarter of 2008. Although net selling prices advanced
approximately 2 percent, sales volumes fell more than 4 percent and
currency effects reduced sales by 1 percent. The higher selling
prices resulted from increases implemented during 2008 across all
categories, net of increased competitive promotional activity, mainly for
Huggies diapers. Sales volumes for Huggies diapers fell about
7 percent
compared to double-digit growth in the year-ago period, and volumes for
the Corporation’s child care brands were down about 6 percent, reflecting
continued category softness. Volume performance in the baby and
child care categories was in line with the Corporation’s expectations and
second quarter market shares in both categories improved sequentially from
first quarter levels. In other areas of the business, sales
volumes for Huggies baby wipes increased at a double-digit rate in the
second quarter, while volumes for the Corporation’s feminine care and
adult incontinence brands fell about 4
percent.
|
|
In
Europe, personal care net sales declined approximately 14 percent in the
quarter, as unfavorable currency exchange rates reduced net sales by
nearly 20 percent. Sales volumes rose about 10 percent, while
net selling prices were down about 4 percent in a continued competitive
promotional environment. The volume gains reflect continued
strength for Huggies diapers in Central Europe, along with improvement in
the Corporation’s four core markets of the U.K., France, Italy and
Spain.
|
|
In
developing and emerging markets, personal care net sales increased
1 percent, as continued double-digit growth in organic sales was
mostly offset by negative currency effects of 16 percent. Net
selling prices improved more than 14 percent and product mix was better by
more than 1 percent in the second quarter. In addition,
overall sales volumes increased approximately 2 percent despite lower
diaper volumes in Australia. The growth in organic sales was
broad-based, with particular strength in China, South Korea, Russia,
Turkey, South Africa, Vietnam, Brazil and the Andean region in Latin
America.
|
·
|
In
North America, net sales of consumer tissue products were essentially even
with the year-ago period, as an increase in net selling prices of nearly 5
percent and slightly higher product mix were offset by a 5 percent
decline in sales volumes. The improvement in net selling prices
reflects list price increases implemented across the bathroom tissue,
paper towel and facial tissue categories during 2008, partially offset by
an increase in competitive promotional activity. The lower
sales volumes reflect the Corporation’s focus on improving revenue
realization, as well as slower category growth and consumer
trade-down. For the quarter, volumes were down approximately 10
percent for Kleenex facial tissue and the Corporation’s paper towel
brands, while overall bathroom tissue volumes fell about 2
percent.
|
|
In
Europe, consumer tissue net sales decreased more than 19 percent
compared with the second quarter of 2008, on weaker foreign currency
exchange rates of almost 19 percent. Sales volumes were nearly
1 percent higher, while net selling prices and product mix each fell
almost 1 percent in the quarter.
|
|
Consumer
tissue net sales in developing and emerging markets declined by
9 percent, primarily due to unfavorable currency effects of nearly 15
percent and a decline in sales volumes of almost
4 percent. These factors were partially offset by higher
net selling prices of more than 8 percent, reflecting the Corporation’s
aggressive actions over the past year to recover inflationary cost
increases and improve profitability. Enhanced product mix also
boosted sales by 1 percent in the
quarter.
|
·
|
Net
sales of K-C Professional (“KCP”) & Other products decreased 12.4
percent compared with the second quarter of 2008. Overall sales
volumes fell about 10 percent, net of an approximate 2 percent benefit
from the acquisition of Jackson Products, Inc. in the second quarter of
2009. Changes in foreign currency rates reduced sales by 7
percent, while higher net selling prices and improved product mix
increased sales by about 3 percent and 2 percent,
respectively. Economic weakness and rising unemployment levels
in North America and Europe had a significant effect on KCP’s categories
in the second quarter. In North America, net sales declined 9
percent. While net selling prices and product mix each improved
1 percent, sales volumes declined 10 percent and currency effects were
negative by about 1 percent. In Europe, KCP’s net sales
declined 25 percent in the second quarter, as sales volumes were nearly 11
percent lower, product mix was down about 2 percent and weaker currencies
reduced sales by 16 percent, while net selling prices increased more
than
|
·
|
Net
sales of health care products increased 9.5 percent in the second
quarter. Sales volumes climbed about 14 percent, while net
selling prices were lower by 1 percent and unfavorable currency exchange
rates reduced sales by 4 percent. Volume growth was broad-based
across most product categories, including continued double-digit growth in
exam gloves. The business continues to benefit from strong
results in nitrile gloves, including the new Lavender offering introduced
late last year. In addition, nearly half of the total gain in
health care volumes in the quarter was attributable to increased global
demand for face masks as a result of the H1N1 flu
virus.
|
Net
Sales
|
2009
|
2008
|
||||
North
America
|
$
|
2,594
|
$
|
2,645
|
||
Outside
North America
|
2,311
|
2,517
|
||||
Intergeographic
sales
|
(178
|
)
|
(156
|
)
|
||
Consolidated
|
$
|
4,727
|
$
|
5,006
|
|
Commentary:
|
·
|
Net
sales in North America declined 1.9 percent primarily due to lower sales
volumes partially offset by higher net selling
prices.
|
·
|
Net
sales outside North America decreased 8.2 percent as higher net selling
prices were more than offset by unfavorable currency effects, particularly
in Europe, South Korea, Australia and
Brazil.
|
Operating
Profit(a)
|
2009
|
2008
|
||||
Personal
Care
|
$
|
394
|
$
|
437
|
||
Consumer
Tissue
|
161
|
130
|
||||
K-C
Professional & Other
|
102
|
111
|
||||
Health
Care
|
62
|
30
|
||||
Other
income and (expense), net(b)(c)
|
(41
|
)
|
(7
|
)
|
||
Corporate
& Other(c)
|
(69
|
)
|
(51
|
)
|
||
Consolidated
|
$
|
609
|
$
|
650
|
(a)
|
Organization
optimization charges (as described in Note 3 to the Consolidated Financial
Statements) are included in the business segments as follows (also shown
is the percentage change in operating profit versus the prior year due to
these charges):
|
Amount
|
Percentage
Variation
|
|||||
Personal
Care
|
$
|
41
|
(9.4
|
)
|
||
Consumer
Tissue
|
42
|
(32.3
|
)
|
|||
K-C
Professional & Other
|
14
|
(12.6
|
)
|
|||
Health
Care
|
6
|
(20.0
|
)
|
|||
Corporate
& Other
|
7
|
(13.7
|
)
|
|||
Total
|
$
|
110
|
(16.9
|
)
|
(b)
|
2009
includes $20 million of currency transaction losses versus
$6 million of currency transaction losses in
2008.
|
(c)
|
Other
income and (expense), net includes $(1) million and Corporate &
Other includes $(14) million of pretax amounts for the
strategic cost reductions in
2008.
|
Percentage Change in Operating Profit Versus Prior Year
|
|||||||||||||||||||||||||||||
Changes Due To
|
|||||||||||||||||||||||||||||
Total
|
Net
|
Input
|
Production
|
||||||||||||||||||||||||||
Change
|
Volume
|
Price
|
Costs(a)
|
Curtailment
|
Currency
|
Other(b)
|
|||||||||||||||||||||||
Consolidated
|
(6.3
|
)
|
(7
|
)
|
35
|
28
|
(7
|
)
|
(19
|
)
|
(36
|
)
|
|||||||||||||||||
Personal
Care
|
(9.8
|
)
|
(3
|
)
|
32
|
6
|
(3
|
)
|
(19
|
)
|
(23
|
)
|
|||||||||||||||||
Consumer
Tissue
|
23.8
|
(12
|
)
|
52
|
81
|
(16
|
)
|
(12
|
)
|
(69
|
)
|
||||||||||||||||||
K-C
Professional &
Other
|
(8.1
|
)
|
(26
|
)
|
23
|
30
|
(21
|
)
|
(8
|
)
|
(6
|
)
|
|||||||||||||||||
Health
Care
|
106.7
|
44
|
(8
|
)
|
49
|
44
|
(8
|
)
|
(14
|
)
|
·
|
Personal
care segment operating profit decreased 9.8 percent as the benefits from
higher net selling prices, cost savings and materials cost deflation were
more than offset by charges for the organization optimization initiative,
increased marketing and general expenses, and unfavorable currency
effects. In North America, operating profit was even with the
prior year as higher net selling prices, cost savings and materials cost
deflation were offset by lower sales volumes, organization optimization
charges and production curtailments. Operating profit in Europe
decreased because cost savings and higher sales volumes were more than
offset by lower net selling prices and charges for the organization
optimization initiative. In the developing and emerging
markets, operating profit declined as higher net selling prices were
offset by unfavorable currency effects, including the previously mentioned
impact of finished product imports in Venezuela, and higher distribution
and marketing costs.
|
·
|
Consumer
tissue segment operating profit increased 23.8 percent on the strength of
higher net selling prices, materials cost deflation and cost savings,
partially offset by charges for the organization optimization initiative,
production curtailments, lower sales volumes and unfavorable currency
effects. Increased operating profit in North America was driven
by the same factors, except for currency effects, that drove the overall
segment improvement. In Europe, operating profit decreased as
somewhat lower net selling prices, production curtailments, organization
optimization charges and unfavorable currency effects more than offset
cost savings and the benefits of materials cost
deflation. Operating profit in the developing and emerging
markets increased primarily due to higher net selling
prices.
|
·
|
Operating
profit for K-C Professional & Other products decreased 8.1 percent as
higher net selling prices and cost deflation were more than offset by
production curtailments, lower sales volumes, charges for the organization
optimization initiative and unfavorable currency
effects.
|
·
|
Health
care segment operating profit increased 106.7 percent because increased
sales volumes, materials cost deflation and manufacturing production
efficiencies more than offset organization optimization
charges.
|
Operating
Profit
|
2009
|
2008
|
||||
North
America
|
$
|
499
|
$
|
458
|
||
Outside
North America
|
220
|
250
|
||||
Other
income and (expense), net (a)(b)
|
(41
|
)
|
(7
|
)
|
||
Corporate
& Other(b)
|
(69
|
)
|
(51
|
)
|
||
Consolidated
|
$
|
609
|
$
|
650
|
(a)
|
2009
includes $20 million of currency transaction losses versus
$6 million of currency transaction losses in
2008.
|
(b)
|
For
the period ended June 30, 2008, Other income and (expense), net includes
$(1) million and Corporate & Other includes $(14) million of
pretax amounts for the
strategic cost reductions.
|
·
|
Operating
profit in North America increased 9.0 percent because higher net selling
prices, cost deflation and cost savings more than offset lower sales
volumes and organization optimization
charges.
|
·
|
Operating
profit outside North America decreased 12.0 percent as higher net selling
prices were offset by production curtailments, organization optimization
charges in Europe and unfavorable currency
effects.
|
|
Additional
Income Statement Commentary
|
·
|
Interest
expense for the second quarter of 2009 was $3 million lower than the prior
year primarily due to lower interest rates partially offset by a higher
average level of debt.
|
·
|
The
Corporation’s effective income tax rate was 29.0 percent in 2009 compared
with 29.8 percent in 2008.
|
·
|
The
Corporation’s share of net income of equity companies in the second
quarter decreased to $44 million from $49 million in 2008, mainly as
a result of lower net income at Kimberly-Clark de Mexico, S.A.B. de C.V.
(“KCM”). Although KCM delivered high single-digit organic sales
growth and improved its gross profit margin, operating profit and net
income comparisons were adversely affected by currency translation
losses. Compared with the second quarter of 2008, the Mexican
peso depreciated on average by more than 20 percent versus the U.S.
dollar.
|
·
|
Net
income attributable to noncontrolling interests was $27 million in the
second quarter of 2009 compared with $34 million in the prior
year. The decrease was primarily due to the acquisition of the
remaining interest in the Corporation’s Andean affiliate in January
2009.
|
Net
Sales
|
2009
|
2008
|
||||
Personal
Care
|
$
|
4,099
|
$
|
4,211
|
||
Consumer
Tissue
|
3,129
|
3,397
|
||||
K-C
Professional & Other
|
1,387
|
1,601
|
||||
Health
Care
|
633
|
604
|
||||
Corporate
& Other
|
27
|
45
|
||||
Intersegment
sales
|
(55
|
)
|
(39
|
)
|
||
Consolidated
|
$
|
9,220
|
$
|
9,819
|
Percent Change in Net Sales Versus Prior Year
|
|||||||||||||||
Changes Due To
|
|||||||||||||||
Total
|
Volume
|
Net
|
Mix/
|
||||||||||||
Change
|
Growth
|
Price
|
Currency
|
Other
|
|||||||||||
Consolidated
|
(6.1
|
)
|
(3
|
)
|
5
|
(9
|
)
|
1
|
|||||||
Personal
Care
|
(2.7
|
)
|
1
|
6
|
(10
|
)
|
-
|
||||||||
Consumer
Tissue
|
(7.9
|
)
|
(4
|
)
|
5
|
(10
|
)
|
1
|
|||||||
K-C
Professional & Other
|
(13.4
|
)
|
(9
|
)
|
4
|
(8
|
)
|
-
|
|||||||
Health
Care
|
4.8
|
9
|
-
|
(4
|
)
|
-
|
·
|
Personal
care net sales declined 2.7 percent as higher net selling prices, in North
America and the developing and emerging markets, were more than offset by
unfavorable currency effects, principally in Europe, South Korea,
Australia, Brazil and Russia.
|
·
|
Consumer
tissue net sales decreased 7.9 percent because unfavorable currency
effects and lower sales volumes more than offset higher net selling
prices. The unfavorable currency effects primarily occurred in
the same countries as personal
care.
|
·
|
Net
sales of K-C Professional & Other products decreased 13.4 percent as
lower sales volumes and unfavorable currency effects, primarily in Europe,
more than offset higher net selling
prices.
|
·
|
Health
care net sales increased 4.8 percent on the strength of higher sales
volumes, tempered by unfavorable currency
effects.
|
Net
Sales
|
2009
|
2008
|
||||
North
America
|
$
|
5,133
|
$
|
5,196
|
||
Outside
North America
|
4,416
|
4,949
|
||||
Intergeographic
sales
|
(329
|
)
|
(326
|
)
|
||
Consolidated
|
$
|
9,220
|
$
|
9,819
|
|
Commentary:
|
·
|
Net
sales in North America declined 1.2 percent due to lower sales volumes
mostly offset by higher net selling
prices.
|
·
|
Net
sales outside North America decreased 10.8 percent as higher net selling
prices were more than offset by unfavorable currency
effects.
|
Operating
Profit(a)
|
2009
|
2008
|
||||
Personal
Care
|
$
|
836
|
$
|
865
|
||
Consumer
Tissue
|
355
|
286
|
||||
K-C
Professional & Other
|
182
|
208
|
||||
Health
Care
|
110
|
76
|
||||
Other
income and (expense), net(b)(c)
|
(118
|
)
|
-
|
|||
Corporate
& Other(c)
|
(128
|
)
|
(121
|
)
|
||
Consolidated
|
$
|
1,237
|
$
|
1,314
|
(a)
|
Organization
optimization charges (as described in Note 3 to the Consolidated Financial
Statements) are included in the business segments as follows (also shown
is the percentage change in operating profit versus the prior year due to
these charges):
|
Amount
|
Percentage
Variation
|
|||||
Personal
Care
|
$
|
41
|
(4.7
|
)
|
||
Consumer
Tissue
|
42
|
(14.7
|
)
|
|||
K-C
Professional & Other
|
14
|
(6.7
|
)
|
|||
Health
Care
|
6
|
(7.9
|
)
|
|||
Corporate
& Other
|
7
|
(5.8
|
)
|
|||
Total
|
$
|
110
|
(8.4
|
)
|
(b)
|
2009
includes $96 million of currency transaction losses versus
$6 million of currency transaction gains in
2008.
|
(c)
|
Other
income and (expense), net includes $(2) million and Corporate &
Other includes $(37) million of pretax amounts for the
strategic cost reductions in
2008.
|
Percentage Change in Operating Profit Versus Prior Year
|
|||||||||||||||||||||||||||||
Changes Due To
|
|||||||||||||||||||||||||||||
Total
|
Net
|
Input
|
Production
|
||||||||||||||||||||||||||
Change
|
Volume
|
Price
|
Costs(a)
|
Curtailment
|
Currency
|
Other(b)
|
|||||||||||||||||||||||
Consolidated
|
(5.9
|
)
|
(6
|
)
|
38
|
19
|
(10
|
)
|
(21
|
)
|
(26
|
)
|
|||||||||||||||||
Personal
Care
|
(3.4
|
)
|
(1
|
)
|
30
|
4
|
(5
|
)
|
(14
|
)
|
(17
|
)
|
|||||||||||||||||
Consumer
Tissue
|
24.1
|
(15
|
)
|
62
|
49
|
(20
|
)
|
(10
|
)
|
(42
|
)
|
||||||||||||||||||
K-C
Professional &
Other
|
(12.5
|
)
|
(21
|
)
|
30
|
26
|
(24
|
)
|
(8
|
)
|
(16
|
)
|
|||||||||||||||||
Health
Care
|
44.7
|
21
|
(3
|
)
|
33
|
20
|
(7
|
)
|
(19
|
)
|
(a)
|
Includes
raw materials cost deflation and energy and distribution
variations.
|
(b)
|
Includes
organization optimization charges as noted
above.
|
·
|
Personal
care segment operating profit declined 3.4 percent as higher net selling
prices and cost savings were more than offset by production curtailments,
the organization optimization charges and unfavorable currency
effects.
|
·
|
Consumer
tissue segment operating profit increased 24.1 percent because higher net
selling prices, materials cost deflation and cost savings more than offset
the organization optimization charges, production curtailments and
unfavorable currency effects.
|
·
|
Operating
profit for K-C Professional & Other products decreased 12.5 percent as
lower sales volumes, production curtailments, the organization
optimization charges and unfavorable currency effects more than offset
materials cost deflation, cost savings and higher net selling
prices.
|
·
|
Health
care segment operating profit increased 44.7 percent due to higher sales
volumes, materials cost deflation and manufacturing production
efficiencies.
|
·
|
The charges included in other income and
(expense), net for the first six months of 2009 are primarily related to
currency transaction losses, with an approximate two-thirds of these
transaction losses being related to conversion of local currency cash
balances to U.S. dollars at the Corporation’s Venezuelan
subsidiary. Also included is the previously mentioned
non-cash charge related to one of the Corporation’s financing
entities.
|
Operating
Profit
|
2009
|
2008
|
||||
North
America
|
$
|
1,004
|
$
|
927
|
||
Outside
North America
|
479
|
508
|
||||
Other
income and (expense), net(a)(b)
|
(118
|
)
|
-
|
|||
Corporate
& Other(b)
|
(128
|
)
|
(121
|
)
|
||
Consolidated
|
$
|
1,237
|
$
|
1,314
|
(a)
|
2009
includes $96 million of currency transaction losses versus
$6 million of currency transaction gains in
2008.
|
(b)
|
For
the period ended June 30, 2008, Other income and (expense), net includes
$(2) million and Corporate & Other includes $(37) million of
pretax amounts for the
strategic cost reductions.
|
·
|
Operating
profit in North America increased 8.3 percent primarily due to higher net
selling prices, materials cost deflation and cost
savings.
|
·
|
Operating
profit outside North America decreased 5.7 percent because of unfavorable
currency effects, production curtailments and organization optimization
charges in Europe.
|
·
|
Interest
expense for the first six months of 2009 was $4 million lower than the
prior year primarily due to lower interest rates partially offset by a
higher average level of debt.
|
·
|
The
Corporation’s effective tax rate was 29.1 percent in 2009 compared with
28.7 percent in 2008.
|
·
|
The
Corporation’s share of net income of equity companies decreased to $76
million from $92 million in 2008. The decrease was principally
due to lower net income at KCM primarily as a result of currency
translation losses.
|
·
|
Net
income attributable to noncontrolling interests was $51 million in 2009
compared with $69 million in the prior year. The decrease was
primarily due to the acquisition of the remaining interest in the
Corporation’s Andean affiliate in January
2009.
|
·
|
Cash
provided by operations for the first six months of 2009 was
$1.7 billion, an increase of approximately 41 percent from
$1.2 billion in the prior year. The improvement was driven
by a significant reduction in working capital, including
inventories. These benefits were partially offset by increased
pension plan contributions. Contributions to the Corporation’s
defined benefit pension plans totaled approximately $495 million in 2009
versus $53 million in 2008.
|
·
|
Capital
spending for the first six months was $396 million compared with $434
million last year and is essentially in line with the Corporation’s plan
to spend $800 to $850 million this
year.
|
·
|
At
June 30, 2009, total debt and redeemable securities was $6.9 billion
compared with $7.0 billion at the end of
2008.
|
·
|
During
the second quarter of 2009, the Corporation acquired Jackson Products,
Inc., a privately held safety products company, for approximately $155
million. This acquisition is consistent with the Corporation’s
global business plan strategy to accelerate growth of high-margin
workplace products sold by its Kimberly-Clark Professional
business.
|
·
|
Management
believes that the Corporation’s ability to generate cash from operations
and its capacity to issue short-term and long-term debt are adequate to
fund working capital, capital spending, payment of dividends and other
needs in the foreseeable future.
|
Month
|
Shares
|
Amount
|
|||
April
|
101,357
|
$
|
5,029,102
|
||
May
|
38
|
1,894
|
|||
June
|
-
|
-
|
KIMBERLY-CLARK
CORPORATION
|
|
(Registrant)
|
By:
|
/s/ Mark A.
Buthman
|
Mark
A. Buthman
|
|
Senior
Vice President and
|
|
Chief
Financial Officer
|
|
(principal
financial officer)
|
By:
|
/s/ Randy J.
Vest
|
Randy
J. Vest
|
|
Vice
President and Controller
|
|
(principal
accounting officer)
|
|
|
(3)a.
|
Amended
and Restated Certificate of Incorporation, dated April 30, 2009,
incorporated by reference to Exhibit No. (3)a of the Corporation’s Current
Report on Form 8-K dated May 1,
2009.
|
|
(3)b.
|
By-Laws,
as amended April 30, 2009, incorporated by reference to
Exhibit No. (3)b of the Corporation’s Current Report on
Form 8-K dated May 1, 2009.
|
|
(4).
|
Copies
of instruments defining the rights of holders of long-term debt will be
furnished to the Securities and Exchange Commission on
request.
|
|
(31)a.
|
Certification
of Chief Executive Officer required by Rule 13a-14(a) or
Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), filed
herewith.
|
|
(31)b.
|
Certification
of Chief Financial Officer required by Rule 13a-14(a) or
Rule 15d-14(a) of the Exchange Act, filed
herewith.
|
|
(32)a.
|
Certification
of Chief Executive Officer required by Rule 13a-14(b) or
Rule 15d-14(b) of the Exchange Act and Section 1350 of
Chapter 63 of Title 18 of the United States Code, furnished
herewith.
|
|
(32)b.
|
Certification
of Chief Financial Officer required by Rule 13a-14(b) or
Rule 15d-14(b) of the Exchange Act and Section 1350 of
Chapter 63 of Title 18 of the United States Code, furnished
herewith.
|
|
(101).INS*
|
XBRL
Instance Document
|
|
(101).SCH*
|
XBRL
Taxonomy Extension Schema Document
|
|
(101).CAL*
|
XBRL
Taxonomy Extension Calculation Linkbase
Document
|
|
(101).LAB*
|
XBRL
Taxonomy Extension Label Linkbase
Document
|
|
(101).PRE*
|
XBRL
Taxonomy Extension Presentation Linkbase
Document
|
|
* Attached
as Exhibit 101 to this report are the following documents formatted in
XBRL (Extensible Business Reporting Language): (i) Consolidated Income
Statement for the three and six months ended June 30, 2009 and 2008,
(ii) Condensed Consolidated Balance Sheet at June 30, 2009 and
December 31, 2008, (iii) Condensed Consolidated Cash Flow Statement
for the six months ended June 30, 2009 and 2008, (iv)
Consolidated Statement of Comprehensive Income for the three
and six months ended June 30, 2009 and 2008, and (v) Notes to Consolidated
Financial Statements. Users of this data are advised pursuant to Rule 406T
of Regulation S-T that this interactive data file is deemed not filed or
part of a registration statement or prospectus for purposes of sections 11
or 12 of the Securities Act of 1933, is deemed not filed for purposes of
section 18 of the Securities Exchange Act of 1934, and otherwise is not
subject to liability under these
sections.
|